Brief: Gensight Biologics Reports Topline Results From Reflect Phase III Clinical Trial

Gensight Biologics SA

30/06/2021 06:32

June 30 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS REPORTS TOPLINE RESULTS FROM REFLECT
PHASE
III CLINICAL TRIAL, CONFIRMING LUMEVOQ® EFFICACY INCLUDING
BETTER EFFICACY WITH BILATERAL TREATMENT
    * STATISTICALLY SIGNIFICANT VISUAL ACUITY IMPROVEMENT FROM
BASELINE AND NADIR IN LUMEVOQ®-TREATED EY
    * BETTER EFFICACY FOR BILATERALLY TREATED SUBJECTS
    * CONTRALATERAL EFFECT CONFIRMED, AS DEMONSTRATED IN REVERSE
AND
RESCUE TRIAL
    * FAVORABLE SAFETY PROFILE FOR BILATERAL TREATMENT
    * EFFICACY DEMONSTRATED EVEN MORE CLEARLY IN VISUAL ACUITY
IMPROVEMENT FROM NADIR
    * BILATERAL INJECTIONS HAVE FAVORABLE SAFETY PROFILE

Source text for Eikon:  ID:nBw4VLCcpa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))